By blocking C5, and hence stopping the cascade that leads to C9 drilling a hole in the red cell, ECULIZUMAB,
a humanized anti C5 monoclonal antibody, considerably decreases hemolysis in patients with PNH Paroxysmal
Nocturnal
Hemoglobinuria
whose red cells lack a surface protein that protects them from the action of "Complement".
Complement is a complex system of proteins that protects us against infection and abnormal cell proliferation.
